Survival times improved in favipiravir-treated Ebola patients - Healio

-

Treatment with favipiravir, an experimental antiviral, improved the survival time of patients with Ebola virus disease during the West African epidemic, study findings showed.

Favipiravir (Toyama) was one of several investigational therapies tested during the epidemic, which infected more than 28,000 people and killed over 11,300, mostly in Guinea, Liberia and Sierra Leone. It is currently being evaluated again in a pioneering multidrug trial during the current Ebola outbreak in the Democratic Republic of the Congo.

In a retrospective study, Romy Kerber, PhD, a scientist in the department of virology at the Bernhard Nocht Institute for Tropical Medicine, and colleagues assessed the outcomes of 163 patients diagnosed with Ebola virus disease in 2015 in Guinea, including 73 who were treated with favipiravir.

Results showed that the case fatality rate in favipiravir-treated patients was lower than that in untreated patients — 42.5% and 57.8%, respectively. Kerber and colleagues said the findings revealed “a trend toward improved survivability” among patients treated with favipiravir, though they found that the effect was not statistically significant.

According to the study, in the multivariate regression analysis, higher cycle threshold (Ct) value and younger age were associated with survival (P < 0.001) and favipiravir treatment showed no significant effect (P = 0.11). However, an analysis of survival time revealed a statistically significant difference that indicated prolonged survival in the favipiravir-treated group (P = 0.015).

Kerber and colleagues said the findings were consistent with those from the JIKI trial, which indicated that favipiravir may reduce mortality rates among patients with Ebola virus and lower viral loads.

“Pharmacokinetics data in [Ebola virus disease] patients enrolled in the JIKI trial revealed drug concentrations lower than targeted. Therefore, it is conceivable that administrating higher doses of favipiravir, increasing its bioavailability, or modulating its metabolism could enhance its therapeutic effect,” Kerber and colleagues wrote. “In conclusion, the observations made so far with favipiravir including those presented here call for further preclinical and clinical studies to better understand pharmacokinetics, pharmacodynamics, and adverse events at various dosing schemes and application forms.” – by Caitlyn Stulpin

Disclosures: The authors report no relevant financial disclosures.



https://ift.tt/2FJncPi

Comments

Post a Comment

Popular posts from this blog

A Russian lab containing smallpox and Ebola exploded - Vox.com

-
Image
Russia’s State Research Center of Virology, in the city of Koltsovo in Siberia, has one of the largest collections of dangerous viruses anywhere in the world. During the Cold War, the lab developed biological weapons and defenses against them, and it reportedly stored dangerous strains of smallpox, anthrax, and Ebola among other viruses. So lots of people were concerned when an explosion ripped through the facility on Monday. According to Russian independent media , the laboratory was undergoing repairs when a gas bottle exploded, sparking a 30-square-meter fire that left one worker severely burned. Glass throughout the building was reportedly destroyed in the blast, and the fire reportedly spread through the building’s ventilation system . The lab is one of only two in the world known to still have samples of smallpox, which was eradicated from the wild in 1977. The other is in the United States . Experts say that under certain circumstances, an explosion could lead to the releas
Read more

Azar calls for transparency in Ebola-like death in Tanzania | TheHill - The Hill

-
Image
Health and Human Services Secretary Alex Azar on Monday called for transparency from Tanzanian officials in the case of a patient who recently died after suffering Ebola-like symptoms, The Associated Press  reported . Azar told reporters in Uganda that he and others are “very concerned” and urged Tanzania’s government to share lab results related to the case. ADVERTISEMENT Congo, which borders Tanzania, is in the midst of the second-deadliest Ebola outbreak in history, with confirmed cases now exceeding 3,000. Azar said efforts were underway to secure Tanzania’s compliance with international health regulations and obligations to the World Health Organization (WHO) “to protect Tanzanians as well as all people in the region," according to the AP. Tanzania’s government said Saturday there is no confirmed case of Ebola inside its borders. According to an internal WHO document obtained by AP, the patient, a 34-year-old woman, died on Sept. 8 and was buried the same day. The
Read more

Ebola: Symptoms, treatment, and causes

-
Image
diabetes global epidemic :: Article Creator 32 Countries With The Highest Rates Of Diabetes In this article, we will be taking a look at the 32 countries with the highest rates of diabetes. If you do not want to learn about the global diabetes market, head straight to the 5 Countries with the Highest Rates of Diabetes. The Global Diabetes Market and Its Implications  The global diabetes market is experiencing significant growth and poses a substantial challenge to public health worldwide. According to the IDF Diabetes Atlas, in 2021, approximately 537 million people were suffering from diabetes globally, a number expected to rise to 643 million by 2030 and 783 million by 2045. This increase in prevalence underscores the urgent need for effective measures to address this chronic disease.  In the United States, the diabetes market is substantial, with around 136 million adults diagnosed with diabetes or in a prediabetic condition as reported by t
Read more